The Isoform GC1f of the Vitamin D Binding Protein Is Associated with Bronchiectasis Severity

Martina Oriano 1,2,*, Stefano Aliberti 3,4,*, Franca Rosa Guerini 5,*, Cristina Agliardi 5, Carlotta Di Francesco 1,2,*, Alice Gelmini 1,2, Leonardo Terranova 1,2, Milena Zanzottera 5, Paola Marchisio 1,6,*, Mario Clerici 1,5,*, and Francesco Blasi 1,2

Abstract: Vitamin D modulates immune responses and its deficiency has been observed in more than 60% of bronchiectasis patients. Vitamin D binding protein (DBP) is coded by the GC gene, is involved in the transport of vitamin D, and includes a number of isoforms based on single nucleotide polymorphisms (SNPs) in the coding region at rs7041 and rs4855. We evaluated the possible clinical impact of DBP polymorphisms and isoforms in an observational, cross-sectional study conducted in 116 bronchiectasis patients, who were genetically characterized for rs4588 and rs7041 SNPs. Results showed that the GC1f isoform (rs7041/rs4588 A/G) correlated with a more severe disease (18.9% vs. 6.3%, p = 0.038), a higher incidence of chronic infections (63.6% vs. 42%, p = 0.041), and a lower BACI score (0.0 (0.0, 2.5) vs. 3.0 (0.0, 3.0), p = 0.035). Moreover, blood concentration of vitamin D was higher in patients carrying GC1s (median (IQR): 20.5 (14.3, 29.7 vs. 15.8 (7.6, 22.4), p = 0.037)). Patients carrying GC1f isoform have a more severe disease, more chronic infections and lower asthmatic comorbidity in comparison to those without the GC1f isoform. Presence of the GC1s isoform (rs7041/rs4858 C/G) seems to be associated to a milder clinical phenotype with increased vitamin D levels and lower comorbidities score.

1. Introduction

Bronchiectasis is a chronic respiratory disease characterized by abnormal dilation of bronchi with patients experiencing daily cough, sputum production and frequent exacerbations [1]. Pulmonary infections often become chronic leading to a vicious circle of airway inflammation [2]. Host–pathogen interaction is, nowadays, a hot topic in bronchiectasis investigations, and the identification of treatable traits is one of the main interests of both scientists and clinicians [3].

Among candidate treatable traits in bronchiectasis, vitamin D and its pathway seem to be among the most promising. Vitamin D is involved in pulmonary immunity and its deficiency has been observed in more than 60% of bronchiectasis patients [4,5] and correlates to disease and radiological severity, increased airway inflammation and poor quality of life [4,5]. Vitamin D binding protein (DBP) is involved in the transport of vitamin D,
D, expressed in different tissues, and produced also by neutrophils. Other functions of this protein include macrophage activation after conversion to macrophage-activating factor (DBP-MAF) by enzymes released from lymphocytes, modulation of neutrophils and monocytes chemotaxis through the increased production of C5-derived peptides and actin scavenging [6–9].

DBP is coded by the single copy GC gene (NCBI GENE ID2638) [6]. A great number of genetic variants have been identified both in the intronic and exonic portion of this gene. Isoforms of this protein were isolated through functional studies, and now we know that they are based on single nucleotide polymorphisms (SNPs) in the coding region at rs4855 and rs7041. SNPs and isoforms of DBP have been associated with asthma and COPD [6,10–12]. No data are available to date in bronchiectasis. Vitamin D regulates more than 900 genes and it is involved in both innate and adaptive immunity. Polymorphisms in the GC gene can be involved in both vitamin D bioavailability and have also direct effects on immunity in lungs and, therefore, on the patient’s disease state [13,14].

For these reasons, the aim of this work was to evaluate the impact of DBP polymorphisms and isoforms on bronchiectasis patients’ characteristics.

2. Materials and Methods

2.1. Study Design and Population

This observational, cross-sectional study enrolled consecutive adults (aged ≥18 years) with bronchiectasis referring to the Bronchiectasis Program of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, between March 2017 and March 2019. Patients with clinically (daily sputum production) and radiologically significant bronchiectasis (at least one lobe involvement on chest CT) enrolled during clinical stability (at least 1 month apart from the last exacerbation and antibiotic course). Patients with cystic fibrosis or traction bronchiectasis due to pulmonary fibrosis were excluded along with patients under supplementation with vitamin D. Informed consent was obtained from all the subjects prior to inclusion in the study. The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the institutional review board of Institute (Comitato Etico Milano Area 2, #255_2020, 8 April 2020).

2.2. Study Procedures

Peripheral blood samples were collected from all bronchiectasis patients. Patients underwent clinical, radiological, microbiological, quality of life and functional evaluation during routine visits. We carried out 25-hydroxy vitamin D blood test, immunological functionality and white blood cells count as per clinical practice.

2.3. GC Single Nucleotide Polymorphisms (SNPs) Genotyping

GC SNMPs (rs4588 and rs7041) were evaluated by allelic discrimination real-time PCR using pre-designed TaqMan® probes (C___8278879_10, and C___3133594_30 assays respectively, ThermoFisher Scientific, Waltham, MA, USA) on DNA extracted from peripheral blood using the QIAasympy platform as per the manufacturer’s instructions. The PCR consisted of a hot start at 95 °C for 10 min followed by 40 cycles of 94 °C for 15 s and 60 °C for 1 min. Fluorescence detection (VIC and FAM fluorophores) takes place at a temperature of 60 °C. All assays were performed in 10 µL reactions, using TaqMan Genotyping Master Mix and 20 ng of DNA on 96-well plates using a CFX96 instrument (Bio-Rad, Hercules, CA, USA). Control samples representing all possible genotypes and a negative control were included in each reaction [15].

Polymorphisms were considered throughout the manuscript as: SNMPs genotype, allele, isoform and isoforms’ phenotype. Isoforms genotype in the two loci are provided in Table 1.
2.4. Clinical Evaluation

Disease severity was assessed through both Bronchiectasis Severity Index (BSI) and FACED score (evaluating FEV$_1$, Age, Chronic infection with Pseudomonas, Radiological Extension and Dyspnea) [16,17]. A modified Reiff score was used to assess radiological severity of bronchiectasis. It rates the number of involved lobes (with the lingula considered to be a separate lobe) and the degree of dilatation (range: 1–18) [18]. All bacteriology was performed on spontaneous sputum samples as previously described [19]. Murray-Washington criteria for sputum quality were used in all cases, with all samples having less than 10 squamous cells and more than 25 leukocytes per low-power microscope field. Chronic infection is defined as 2 isolation of the same bacteria at least 3 months apart over 12 period [20]. Quality of life was assessed through the Quality of life -Bronchiectasis (QoL-B) questionnaire [21]. Asthma was diagnosed according to the latest international guidelines (Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Available online: https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention accessed on 2 April 2021).

2.5. Statistical Analysis

Variables were collected in an ad hoc electronic form. Qualitative variables were summarized with absolute and relative (percentage) frequencies, whereas quantitative variables with medians (interquartile ranges, IQR). Differences between groups were statistically assessed with chi-squared or Fisher exact tests when appropriate for qualitative variables, whereas with Mann–Whitney tests for quantitative non-parametric variables. A two-tailed $p$-value was considered statistically significant when less than 0.05. Analyses were performed considering genotype, allele, isoform and isoform phenotype for the considered SNPs. The statistical software SPSS version 25 (IBM, Armonk, NY, USA) was used for all statistical computations.

3. Results

We included 116 bronchiectasis patients (78 (67.2%) female, age median (IQR) 62.0 (48.8, 72.0)) in the study. Vitamin D concentration in blood was median (IQR) 20.4 (13.0, 28.4) ng/mL. A full description of clinical characteristics of the study population is reported in Table S1 of supplementary file.

Frequency of DBP isoforms and isoform phenotypes is reported in Table 2. GC1s isoform was found in 95 (81.9%) of the enrolled patients, GC2 in 55 (47.4%) and GC1f in 37 (31.9%).

Table 1. Isoform genotype in rs7041 and rs4588.

| Isoform | GC rs7041 | GC rs4588 |
|---------|-----------|-----------|
| GC1f    | A         | G         |
| GC1s    | C         | G         |
| GC2     | A         | T         |

Table 2. Isoforms of vitamin D binding protein (DBP) in bronchiectasis patients.

| Isoform Phenotype | Genotype (rs7041/rs4588) | Bronchiectasis n (%) |
|------------------|--------------------------|----------------------|
| GC1f-GC1f        | A/G-A/G                  | 0 (0)%               |
| GC1s-GC1f        | C/G-A/G                  | 24 (20.7)%           |
| GC1s-GC1s        | C/G-C/G                  | 37 (31.9)%           |
| GC1s-GC2         | C/G-A/T                  | 34 (29.3)%           |
| GC1f-GC2         | A/G-A/T                  | 13 (11.2)%           |
| GC2-GC2          | A/T-A/T                  | 8 (6.9)%             |
Full description of rs7041 and rs4588 alleles and genotypes are reported in Table S2 of supplementary file.

3.1. GC Isoforms and Clinical Characteristics

3.1.1. GC1f Isoform

A significant difference in disease severity measured with FACED score was found between GC1f and the other isoforms (FACED severe, n (%): GC1f 7 (18.9%) vs. other isoforms 5 (6.3%), \( p = 0.038 \)).

Chronic infection was higher in patients with GC1f isoform 12 (63.6%) compared to the others 29 (42%), \( (p = 0.041 \)), although no differences in terms of chronic infection by specific bacteria were found in the study groups.

Patients with GC1f isoform showed higher values at QoL-B emotional section [median (IQR): GC1f 83.3 (75–100) compared to the other isoforms 75 (50–89.6), \( p = 0.019 \)], along with a lower asthma prevalence as comorbidity [GC1f 2 (5.4%) vs. other isoforms 18 (22.8%), \( p = 0.032 \)].

Full comparison of the study groups is reported in Table 3.

Table 3. Comparison of clinical characteristics of patients with GC1f isoform vs. others.

| Demography | GC1f (N = 37) | Other Isoforms (N = 79) | p-Value |
|------------|--------------|-------------------------|---------|
| Sex (Female) | 26 (70.3%) | 52 (65.8%) | 0.634 |
| Age | 61.0 (53.0, 71.0) | 63.0 (48.0, 72.0) | 0.526 |
| BMI | 22.0 (19.0, 25.0) | 21.7 (19.0, 24.2) | 0.902 |
| Radiology | | | |
| Reiff score | 4.0 (3.0, 6.0) | 4.0 (3.0, 4.5) | 0.615 |
| Disease Severity | | | |
| BSI score | 7.0 (4.0, 10.0) | 6.0 (3.5, 9.0) | 0.318 |
| BSI risk classes | mild 11 (29.7%) | 29 (36.7%) | 0.675 |
| | moderate 12 (32.4%) | 26 (32.9%) | |
| | severe 14 (37.8%) | 24 (30.4%) | |
| BSI Moderate-severe | 26 (70.3%) | 50 (63.3%) | 0.461 |
| BSI Severe | 14 (37.8%) | 24 (30.4%) | 0.425 |
| FACED score | 2.0 (1.0, 4.0) | 2.0 (1.0, 4.0) | 0.669 |
| FACED risk classes | mild 21 (56.8%) | 42 (53.2%) | 0.055 |
| | moderate 9 (24.3%) | 32 (40.5%) | |
| | severe 7 (18.9%) | 5 (6.3%) | |
| FACED Moderate–severe | 16 (43.2%) | 37 (46.8%) | 0.717 |
| FACED Severe | 7 (18.9%) | 5 (6.3%) | 0.038 |
| Clinical Status | | | |
| Exacerbation in the previous year | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 0.887 |
| Hospitalization (at least one previous year) | 7 (19.4%) | 6 (7.6%) | 0.063 |
| Comorbidities | | | |
| BACI | 0.0 (0.0, 3.0) | 0.0 (0.0, 3.0) | 0.505 |
| Osteoporosis | 2 (5.4%) | 6 (7.6%) | 0.664 |
| Depression | 2 (5.4%) | 10 (12.7%) | 0.232 |
| Anxiety | 1 (2.7%) | 4 (5.1%) | 0.56 |
| Asthma | 2 (5.4%) | 18 (22.8%) | 0.021 |
| Lung Function | | | |
| FEV1% | 79.5 (69.8, 102.0) | 84.5 (69.2, 98.5) | 0.602 |
| FEV1% < 50% | 6 (16.7%) | 9 (11.5%) | 0.451 |
| FEV1% < 35% | 3 (8.3%) | 5 (6.4%) | 0.709 |


| Demography | GC1f (N = 37) | Other Isoforms (N = 79) | p-Value |
|------------|---------------|-------------------------|---------|
| **Standard Microbiology** | | | |
| Chronic infection | 21 (57.6%) | 29 (36.7%) | 0.041 |
| Chronic *P. aeruginosa* | 12 (36.4%) | 18 (26.1%) | 0.287 |
| Chronic *H. influenzae* | 2 (6.1%) | 4 (5.8%) | 0.958 |
| Chronic MSSA | 4 (12.1%) | 4 (5.8%) | 0.266 |
| Chronic *A. xylosoxidans* | 1 (3.0%) | 1 (1.4%) | 0.59 |
| Chronic Others | 2 (2.9%) | 2 (6.1%) | 0.441 |
| **Aetiology** | | | |
| Idiopathic | 17 (45.9%) | 46 (58.2%) | | |
| Primary Ciliary Dyskinesia | 5 (13.5%) | 5 (6.3%) | | |
| Primary immunodeficiency | 4 (10.8%) | 9 (11.4%) | 0.477 |
| Post Infective | 3 (8.1%) | 3 (3.8%) | | |
| Secondary Immunodeficiency | 4 (10.8%) | 2 (2.5%) | | |
| Others * | 4 (10.8%) | 14 (17.8%) | | |
| **QoL-B Questionnaire** | | | |
| Physical section | 66.7 (43.4, 86.7) | 60.0 (41.3, 80.0) | 0.459 |
| Role section | 70.0 (53.3, 93.3) | 66.7 (49.2, 86.7) | 0.502 |
| Vitality section | 61.2 (44.4, 77.8) | 55.6 (33.3, 66.7) | 0.232 |
| Emotion section | 83.3 (75.0, 100.0) | 75.0 (50.0, 85.4) | 0.019 |
| Social section | 75.0 (39.6, 91.7) | 58.3 (41.7, 83.3) | 0.452 |
| Treatment Burden section | 77.8 (58.4, 77.8) | 66.7 (55.6, 77.8) | 0.095 |
| Health section | 44.4 (33.3, 66.7) | 37.5 (16.7, 58.3) | 0.25 |
| Respiration section | 74.1 (66.7, 81.5) | 74.1 (58.3, 81.5) | 0.451 |
| **Vitamin D** | | | |
| Vitamin D (ng/mL) | 20.2 (11.0, 26.0) | 20.4 (14.8, 29.1) | 0.224 |

*Other includes COPD, Connective Tissue Diseases, Alpha1-antitrypsin deficiency, ABPA, Asthma, CFTR-RD, Aspiration. BSI: Bronchiectasis severity index; BACI: Bronchiectasis Aetiology and Co-Morbidity Index; FEV1: Forced expiratory volume first second.

3.1.2. GC1s Isoform

Patients with GC1s were similar to the other isoforms in all clinical characteristics but vitamin D peripheric blood levels were higher in the group carrying this isoform GC1s 20.5 (14.3, 29.7) vs. others 15.8 (7.6, 22.4), (p = 0.037). Moreover, BACI score was significantly lower in GC1s: 0.0 (0.0, 2.5) vs. other isoforms: 3.0 (0.0, 3.0), (p = 0.035), although no difference in the comorbidities that may be associated to vitamin D deficiency was found (Table 4).

3.1.3. GC2 Isoform

Patients with GC2 showed a lower rate of hospitalization in the year prior enrolment (GC2 2 (3.6%) vs. other isoforms 11 (18.0%), p = 0.015) along with a decreased incidence of osteoporosis (GC2 1 (1.8%) vs. other isoforms 7 (11.5%), p = 0.04) (Table S3 of the supplementary file).

3.2. GC Isoform Phenotypes and Clinical Characteristics

Hospitalization rate was increased in patients with GC1s-GC1f and GC2-GC2 in comparison to GC1f-GC2 (GC1s-GC2 0 (0.0%) vs. GC2-GC2 2 (25.0%), p = 0.003; GC1s-GC1f 7 (29.2%) vs. GC1s-GC2 0 (0.0%), p = 0.001). Moreover, asthmatic comorbidity was less frequent in patients with GC1s-GC1f 1 (4.2%) vs. GC2-GC2 4 (50.0%), (p = 0.002). Full comparison of the study groups is reported in Table S4 of supplementary file.
Table 4. Comparison of clinical characteristics of patients with GC1s isoform vs. others.

| Demography | GC1s (N = 95) | Other Isoforms (N = 21) | p-Value |
|------------|--------------|-------------------------|---------|
| Sex (Female) | 64 (67.4%) | 14 (66.7%) | 0.951 |
| Age | 62.0 (48.0, 72.0) | 62.0 (49.0, 71.0) | 0.991 |
| BMI | 21.6 (19.0, 24.2) | 22.0 (19.0, 26.0) | 0.397 |

| Radiology | | | |
|-----------|--------------|-------------------------|---------|
| Reiff score | 4.0 (3.0, 5.5) | 4.0 (3.0, 6.0) | 0.746 |

| Disease Severity | | | |
|------------------|--------------|-------------------------|---------|
| BSI score | 6.0 (3.5, 9.0) | 6.0 (4.0, 10.0) | 0.793 |
| BSI risk classes | | | |
| mild | 33 (34.7%) | 7 (33.3%) | 0.993 |
| moderate | 31 (32.6%) | 7 (33.3%) | |
| severe | 31 (32.6%) | 7 (33.3%) | |
| BSI Moderate-severe | 62 (65.3%) | 14 (66.7%) | 0.903 |
| BSI Severe | 31 (32.6%) | 7 (33.3%) | 0.951 |
| FACED score | 2.0 (1.0, 4.0) | 3.0 (2.0, 4.0) | 0.3 |
| FACED risk classes | | | |
| mild | 53 (55.8%) | 10 (47.6%) | 0.722 |
| moderate | 33 (34.7%) | 8 (38.1%) | |
| severe | 9 (9.5%) | 3 (14.3%) | |
| FACED Moderate-severe | 42 (44.2%) | 11 (52.4%) | 0.496 |
| FACED Severe | 9 (9.5%) | 3 (14.3%) | 0.512 |

| Clinical Status | | | |
|-----------------|--------------|-------------------------|---------|
| Exacerbation in the previous year | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 0.449 |
| Hospitalization (at least one previous year) | 11 (11.6%) | 2 (10.0%) | 0.839 |

| Comorbidities | | | |
|----------------|--------------|-------------------------|---------|
| BACI | 0.0 (0.0, 2.5) | 3.0 (0.0, 3.0) | 0.035 |
| Osteoporosis | 8 (8.4%) | 0 (0.0%) | 0.168 |
| Depression | 12 (12.6%) | 0 (0.0%) | 0.085 |
| Anxiety | 90 (94.7%) | 21 (100.0%) | 0.282 |
| Asthma | 15 (15.8%) | 5 (23.8%) | 0.379 |

| Lung Function | | | |
|----------------|--------------|-------------------------|---------|
| FEV1% | 84.0 (70.0, 101.0) | 83.0 (56.0, 88.0) | 0.233 |
| FEV1% < 50% | 11 (11.8%) | 4 (19.0%) | 0.377 |
| FEV1% < 35% | 5 (5.4%) | 3 (14.3%) | 0.149 |

| Standard Microbiology | | | |
|-----------------------|--------------|-------------------------|---------|
| Chronic infection | 41 (48.2%) | 9 (52.9%) | 0.723 |
| Chronic *P. aeruginosa* | 24 (28.2%) | 6 (35.3%) | 0.56 |
| Chronic *H. influenzae* | 6 (7.1%) | 0 (0.0%) | 0.259 |
| Chronic MSSA | 8 (9.4%) | 0 (0.0%) | 0.188 |
| Chronic *A. xylosoxidans* | 1 (1.2%) | 1 (5.9%) | 0.201 |
| Chronic Others | 3 (3.5%) | 1 (5.9%) | 0.648 |

| Aetiology | | | |
|-----------|--------------|-------------------------|---------|
| Idiopathic | 47 (49.5%) | 16 (76.2%) | |
| Primary Ciliary Dyskinesia | 10 (10.5%) | 0 (0.0%) | 0.739 |
| Primary Immunodeficiency | 9 (9.5%) | 4 (19.0%) | |
| Post Infective | 6 (6.3%) | 0 (0.0%) | |
| Secondary Immunodeficiency | 5 (5.3%) | 1 (4.8%) | |
| Others * | 18 (18.9%) | 0 (0.0%) | |
Table 4. Cont.

Demography

| QoL-B Questionnaire | GC1s (N = 95) | Other Isoforms (N = 21) | p-Value |
|---------------------|---------------|-------------------------|---------|
| Physical section    | 63.4 (41.3, 80.0) | 55.6 (40.0, 70.0) | 0.608   |
| Role section        | 66.7 (53.3, 86.7) | 73.3 (56.9, 90.0) | 0.873   |
| Vitality section    | 55.6 (33.3, 66.7) | 55.6 (44.4, 77.8) | 0.724   |
| Emotion section     | 75.0 (56.2, 91.7) | 75.0 (62.5, 95.8) | 0.684   |
| Social section      | 58.3 (41.7, 83.3) | 83.3 (62.5, 87.5) | 0.147   |
| Treatment Burden section | 66.7 (55.6, 77.8) | 66.7 (55.6, 77.8) | 0.855   |
| Health section      | 37.5 (22.9, 58.3) | 44.4 (23.6, 58.4) | 0.995   |
| Respiration section | 74.1 (58.5, 82.8) | 74.1 (63.0, 77.8) | 0.478   |

Vitamin D

| Vitamin D (ng/mL) | 20.5 (14.3, 29.7) | 15.8 (7.6, 22.4) | 0.037 |

* Other includes COPD, Connective Tissue Diseases, Alpha1-antitrypsin deficiency, ABPA, Asthma, CFTR-RD, Aspiration. BSI: Bronchiectasis severity index; BACI: Bronchiectasis Aetiology and Co-Morbidity Index; FEV1: Forced expiratory volume first second.

4. Discussion

The most important finding of the present study is that bronchiectasis patients with the GC1f isoform have a more severe disease, more frequency of chronic infections and lower asthmatic comorbidity in comparison to those without the GC1f isoform. Moreover, the GC1s isoform seems to be associated to a milder phenotype with increased vitamin D levels and lower comorbidities score (BACI).

Notably, the link between GC1f isoform and clinical/biological data is mainly based on observational data and correlations, not proving any mechanistic rationale.

The effect of GC isoforms on chronic respiratory diseases is various. Studies on asthmatic patients reported GC2 isoform to be associated with asthma susceptibility and to an allergic-like immune response [12,22]. Experiences in COPD reported a decreased disease risk with the GC2 variant, whereas the same isoform was associated with increased risk of bronchiectasis in these patients and SNPs in rs7041 were related to a1-antitrypsin deficiency. The isoform GC1f was reported instead as risk factor in this respiratory disease [22].

Vitamin D in our cohort resulted in being 20.5 ng/mL (median level), higher than in other bronchiectasis patients reported by Chalmers and colleagues [4] (24.7 nmol/L, approximately 9.9 ng/mL) and slightly higher than that presented by Ferri et al., with 17.3 ng/mL [5]. We can speculate that the difference between our cohort and the Scottish one should be caused by a diversity in sun exposure of the two countries. We found an increase of vitamin D levels in patients with GC1s isoform compared to those without this isoform. Data in literature reporting vitamin D serum levels in association with GC isoforms are contradictory. The isoform associated with the lowest levels of vitamin D is GC2, and GC2-GC2 phenotype; however, GC1s is usually associated with an intermediate value of vitamin D [23]. The molecular mechanism underneath the association of low vitamin D blood levels are still unknown [23].

GC1f prevalence seemed related to a severer clinical profile in the disease cohort. Bronchiectasis is a chronic respiratory disease that was associated with chronic infection and inflammation in lungs. Among all the genes activated by the vitamin D pathway, we can find some involved in both innate and adaptive immunity [22]. DBP itself seems to be involved in C5 modulation that leads a modification in neutrophils and monocytes chemotaxis [6]. The association of vitamin D pathway and DBP with immunity reported in literature should explain some of our findings, even if further studies should be needed in order to understand the effect of SNPs in GC in relation to local inflammation and infection in lungs.

The radiological severity evaluated through the Reiff score was not associated with the GC1f isoform. This is not surprising in view of the fact that the Reiff score was not originally
derived in a population of non-cystic fibrosis bronchiectasis and because it might not capture the complexity of the radiological manifestations of the disease (e.g., bronchial wall thickness, sputum plug, etc.). As a consequence of this, in clinical practice discrepancies are often observed between the radiological and the clinical severity due to the presence of several confounders and it being a very complex disease.

Furthermore, it seems that the presence of isoform GC1f does not affect the number of exacerbations, disease duration, or patient’s BMI. Thus the presence and absence of the isoform GC1f might not be closely related to disease progression.

Poor data in literature associated GC1s with respiratory diseases. GC1s-GC1s have been associated in literature with high levels of DBP in sputum of COPD patients and with higher pulmonary obstruction in this disease [24]. Another study reported GC1s variant significantly more frequent in non-smoker controls. Researchers speculated that GC1s may have a role in the detoxification of substances found in smoke [25].

Both rs4588 and rs7041, polymorphisms responsible for the three isoforms, are located in the exon 11 of the GC gene. [6]. These modifications in the amino acid conformation of the protein should lead to functional difference including half-life, affinity to the substrate, cell transit time and others that the scientific community has not fully disclosed yet [6].

These functional differences among isoforms may be involved in the associations we found with clinical data in bronchiectasis.

Strength and Limitations

This study has some limitations. Firstly, this is a monocentric study reporting data from Italy, a south-European country that has a natural higher exposure to sunlight, as a consequence, a bias in vitamin D levels evaluation should have been introduced and this could be one of the reasons explaining why we did not find differences in vitamin D levels among isoforms. Secondly, data regarding reversibility testing, asthma treatments, or pack/years history were not collected, and clinical data on exacerbation rate, antibiotic use, and BMI were missing. All this information would have allowed us to define the role of GC1f across different subpopulations of bronchiectasis patients more precisely.

All these caveats notwithstanding, the study has some potentially interesting clinical implications. Bronchiectasis has a large heterogeneity in symptoms, aetiology, disease severity and biological characteristics, and the identification of a new biomarker could help in the stratification of patients and might contribute to the development of a personalized approach to the disease.

As mentioned above, further studies investigating inflammation and bacterial colonization of lungs, as well as cytological assessment and DBP quantification in association with polymorphisms in the GC gene, should be carried out in the future in order to develop a deeper knowledge of the clinical associations of these genetic factors to bronchiectasis. Moreover, these data on clinical associations in the bronchiectasis cohort should be confirmed in a larger and more generalizable population.

5. Conclusions

In conclusion, we demonstrated an increased disease severity, increased chronic infection in adult patients with the GC1f isoform of DBP, along with an association of the GC1s isoform with a milder phenotype with increased vitamin D levels and a lower comorbidities score. These results may represent a step towards the identification of a new biomarker that should help in the stratification of patients and may contribute to the development of a personalized approach to bronchiectasis treatment.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/biomedicines9111573/s1, Table S1: Clinical characteristics of the study population presented as median (IQR) or n (%), Table S2: SNPs in GC gene in bronchiectasis patients, Table S3: Comparison of clinical characteristics of patients with GC2 isoform vs. other isoforms, Table S4: Comparison of clinical characteristics of patients among isoform phenotypes.
Author Contributions: Conceptualization, M.O. and S.A.; Data curation, M.O. and S.A.; Formal analysis, M.O. and S.A.; Funding acquisition, S.A., M.C. and F.B.; Investigation, M.O., S.A., F.R.G., C.A. and M.Z.; Project administration, S.A.; Resources, S.A., M.C. and F.B.; Supervision, S.A., M.C. and F.B.; Writing—original draft, M.O., S.A., F.R.G. and C.A.; Writing—review and editing, C.D.F., A.G., L.T., P.M., M.C. and F.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Italian Ministry of Health Ricerca Corrente (RC 2020) and the APC was funded by the Italian Ministry of Health Ricerca Corrente (RC 2021). The funders did not have any influence in the design, implementation, analysis or interpretation of the data in this study.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the institutional review board of Institute (Comitato Etico Milano Area 2, #255_2020, 8 April 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy concerns.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Polverino, E.; Goeminne, P.C.; McDonnell, M.J.; Aliberti, S.; Marshall, S.E.; Loebinger, M.R.; Murris-Espin, M.; Cantón, R.; Torres, A.; Dimakou, K.; et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017, 50, 1700629. [CrossRef] [PubMed]
2. Cole, P.J. Inflammation: A two-edged sword—the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 1986, 147, 6–15. [PubMed] [CrossRef] [PubMed]
3. Boaventura, R.; Sibila, O.; Agusti, A.; Chalmers, J.D. Treatable traits in bronchiectasis. Eur. Respir. J. 2018, 52, 1801269. [CrossRef] [PubMed]
4. Chalmers, J.D.; McHugh, B.; Docherty, C.; Govan, J.R.W.; Hill, A.T. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013, 68, 39–47. [CrossRef]
5. Ferri, S.; Crimi, C.; Heffler, E.; Campisi, R.; Noto, A.; Crimi, N. Vitamin D and disease severity in bronchiectasis. Respir. Med. 2019, 148, 1–5. [CrossRef]
6. Malik, S.; Fu, L.; Juras, D.J.; Karmali, M.; Wong, B.Y.L.; Gozdzik, A.; Cole, D.E.C. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit. Rev. Clin. Lab. Sci. 2013, 50, 1–22. [CrossRef]
7. Shah, A.B.; DiMartino, S.J.; Trujillo, G.; Kew, R.R. Selective inhibition of the C5a chemotactic cofactor function of the Vitamin D binding protein by 1,25(OH)2 Vitamin D3. Mol. Immunol. 2006, 43, 1109–1115. [CrossRef]
8. Yamamoto, N.; Homma, S.; Millman, I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J. Immunol. 1991, 147, 273–280.
9. Yamamoto, N.; Kumashiro, R.; Yamamoto, M.; Willett, N.P.; Lindsay, D.D. Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Infect. Immun. 1993, 61, 5388–5391. [CrossRef] [PubMed]
10. Wood, A.M.; Bassford, C.; Webster, D.; Newby, P.; Rajesh, P.; Stockley, R.A.; Thickett, D.R. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011, 66, 205–210. [CrossRef]
11. Home, S.L.; Cockcroft, D.W.; Dosman, J.A. Possible Protective Effect against Chronic Obstructive Airways Disease by the GC 2 Allele. Hum. Genet. 1990, 40, 173–176. [CrossRef]
12. Li, F.; Jiang, L.; Willis-Owen, S.A.; Zhang, Y.; Gao, J. Vitamin D binding protein variants associate with asthma susceptibility in the Chinese han population. BMC Med Genet. 2011, 12, 103–110. [CrossRef] [PubMed]
13. Provvedini, D.M.; Tsoukas, C.D.; Deftos, L.J.; Manolagas, S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221, 1181–1183. [CrossRef]
14. Baeke, F.; Takishii, T.; Korf, H.; Gysenmans, C.; Mathieu, C. Vitamin D: Modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10, 482–496. [CrossRef]
15. Agliardi, C.; Guerini, F.R.; Saresella, M.; Caputo, D.; Leone, M.; Zanzottera, M.; Bolognesi, E.; Marventano, I.; Barizzone, N.; Fasano, M.E.; et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals. Brain Behav. Immun. 2011, 25, 1460–1467. [CrossRef] [PubMed]
16. Chalmers, J.D.; Tohmassen, P.; Aliberti, S.; McDonnell, M.J.; Lonni, S.; Davidson, J.; Poppelwell, L.; Sallik, W.; Pesci, A.; Dupont, L.J.; et al. The Bronchiectasis Severity Index. An International Derivation and Validation Study. Am. J. Respir. Crit. Care Med. 2014, 189, 576–585. [CrossRef]
17. Martinez-Garcia, M.A.; De Gracia, J.; Relat, M.V.; Girón, R-M.; Carro, L.M.; De La Rosa Carrillo, D.; Olveira, C. Multidimensional approach to non-cystic fibrosis bronchiectasis: The FACED score. Eur. Respir. J. 2013, 43, 1357–1367. [CrossRef]
18. Reiff, D.B.; Wells, A.U.; Carr, D.H.; Cole, P.J.; Hansell, D.M. CT findings in bronchiectasis: Limited value in distinguishing between idiopathic and specific types. *Am. J. Roentgenol.* 1995, 165, 261–267. [CrossRef] [PubMed]

19. Chalmers, J.D.; Smith, M.P.; McHugh, B.; Doherty, C.; Govan, J.R.; Hill, A.T. Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis Bronchiectasis. *Am. J. Respir. Crit. Care Med.* 2012, 186, 657–665. [CrossRef] [PubMed]

20. Pasteur, M.C.; Helliwell, S.M.; Houghton, S.J.; Webb, S.C.; Foweraker, J.E.; Coulden, R.A.; Flower, C.D.; Bilton, D.; Keogan, M.T. An Investigation into Causal Factors in Patients with Bronchiectasis. *Am. J. Respir. Crit. Care Med.* 2000, 162, 1277–1284. [CrossRef] [PubMed]

21. Quittner, A.L.; O’Donnell, A.E.; Salathe, M.; Lewis, S.A.; Li, X.; Montgomery, A.B.; O’Riordan, T.G.; Barker, A.F. Quality of Life Questionnaire- Bronchiectasis: Final psychometric analyses and determination of minimal important difference scores. *Thorax* 2015, 70, 12–20. [CrossRef] [PubMed]

22. Chishimba, L.; Thickett, D.; Stockley, R.A.; Wood, A.M. The vitamin D axis in the lung: A key role for vitamin D-binding protein. *Thorax* 2010, 65, 456–462. [CrossRef] [PubMed]

23. Bikle, D.D.; Schwartz, J. Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions. *Front. Endocrinol.* 2019, 10, 317. [CrossRef] [PubMed]

24. Gao, J.; Toröl, T.; Li, C.X.; Ohlmeier, S.; Toljamo, T.; Nieminen, P.; Hattori, N.; Pulkkinen, V.; Iwamoto, H.; Mazur, W. Sputum Vitamin D Binding Protein (VDBP) GC1S/1S Genotype Predicts Airway Obstruction: A Prospective Study in Smokers with COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.* 2020, 15, 1049–1059. [CrossRef] [PubMed]

25. Al-Azzawi, M.A.; Ghoneim, A.H.; Elmadbouh, I. Evaluation of Vitamin D, Vitamin D Binding Protein Gene Polymorphism with Oxidant-Antioxidant Profiles in Chronic Obstructive Pulmonary Disease. *J. Med. Biochem.* 2017, 36, 331–340. [CrossRef]